New drug aims to shield dialysis Patients' brains from 'Brain Fog' and stroke risk

NCT ID NCT07234890

Recruiting now Disease control Sponsor: London Health Sciences Centre Research Institute Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 20, 2026 · Updated 26 times

Summary

This study tests a medication called AV-001 to see if it can protect the brain in people who undergo regular dialysis. Many dialysis patients experience memory problems or mental fogginess. The drug aims to strengthen brain blood vessels and reduce inflammation. The trial will involve 60 adults on dialysis and compare the drug to a placebo using brain scans and blood tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEMODIALYSIS